STOCK TITAN

Medline Inc. announces pricing of secondary offering of Class A common stock

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Medline (Nasdaq: MDLN) priced a secondary offering of 60,000,000 Class A common shares to be sold by existing stockholders. The public price is $35.50 per share, and the sellers granted underwriters a 30-day option to buy up to 9,000,000 additional shares. Medline is not selling shares and will receive no proceeds. The company expects the offering to close on November 23, 2026, subject to customary closing conditions.

Medline and Medline Holdings agreed to buy back $200 million of Class A shares and Medline Holdings limited partnership interests directly from the sellers at the price paid by the underwriters. The repurchase is expected to close alongside the offering and depends on the offering closing, but not the reverse.

Loading...
Loading translation...

Positive

  • Minor point$200 million agreed repurchase covers Class A shares and partnership interests at the price paid by the underwriters
  • Minor point. Forward-looking: it has not happened yet and may not happen.Class B shares will be canceled one-for-one, for no extra payment, if corresponding partnership interests are repurchased

Negative

  • Minor point$200 million repurchase depends on the secondary offering closing; the offering does not depend on the repurchase

News Explained

For any repurchased Medline Holdings limited partnership interests (“Common Units”), the seller must also transfer an equal number of Medline Class B shares to Medline for no additional consideration; when the repurchase closes, Medline will cancel and retire those Class B shares.

Argus 15 min delay 13 alerts
+3.56% vs previous close $39.02 last price 9.5x rel. volume Open Argus
Details

Market Reaction – MDLN

$36.00 – $39.08 Day Range
$51.30B Mkt Cap at Last Price

On Nov 18, the first trading day after this news, the latest delayed price for MDLN is 3.56% above the previous close. Our momentum scanner has recorded 13 alerts for this stock so far that day. The latest delayed price is $39.02. Relative volume is exceptionally heavy at 9.5x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Offering shares: 60,000,000 shares Offering price: $35.50 per share Underwriters’ option: Up to 9,000,000 additional shares; 30-day option +2 more
Offering shares
60,000,000 shares
Secondary offering by selling stockholders
Offering price
$35.50 per share
Price to the public
Underwriters’ option
Up to 9,000,000 additional shares; 30-day option
Granted by the selling stockholders
Repurchase
$200 million
Expected concurrent private transaction at the offering price
Expected offering close
November 23, 2026
Subject to customary closing conditions

Previous Offering Reports

1 past event · Latest: Nov 16
Same Type 1 event
  1. Nov 16

    Offering launch

    24h Move
    -0.8%

    Launched this same secondary offering, including the planned repurchase; today’s announcement sets its price.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

secondary offering, non-underwritten transaction, prospectus, registration statement
4 terms
secondary offering financial
"pricing of its secondary offering of 60,000,000 shares"
A secondary offering is when a company sells new shares of its stock to the public after its initial sale. This allows existing shareholders or the company itself to raise additional money. For investors, it can impact the stock’s price by increasing the total number of shares available, which may influence the stock’s value and how the market perceives the company’s financial health.
View in glossary
non-underwritten transaction financial
"in a private, non-underwritten transaction"
A securities sale conducted without an underwriting firm committing to buy any unsold shares; the issuer or selling shareholders sell directly to investors or through agents on a best-efforts or negotiated basis rather than a firm-commitment underwriting. Because there is no underwriter guarantee, the seller bears the risk that some securities may remain unsold and pricing or timing can be more variable; such transactions include direct placements, best-efforts offerings, and certain registered direct or private placements.
prospectus regulatory
"being made only by means of a prospectus"
A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.
registration statement regulatory
"A registration statement relating to these securities was filed"
A registration statement is a formal document that companies file with a government agency to offer new shares of stock to the public. It provides essential information about the company's finances, operations, and risks, helping investors make informed decisions. Think of it as a detailed product description that ensures transparency and trust before buying into a company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

NORTHFIELD, Ill., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (Nasdaq: MDLN) (“Medline”) announced today the pricing of its secondary offering of 60,000,000 shares of Medline’s Class A common stock by certain selling stockholders affiliated with Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LLC along with GIC Private Limited and its managed affiliate and a wholly owned subsidiary of the Abu Dhabi Investment Authority (collectively, the “Selling Stockholders”) at a price to the public of $35.50 per share (the “Offering”). The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to an additional 9,000,000 shares of Medline’s Class A common stock. The Offering is expected to close on November 23, 2026, subject to customary closing conditions.

Medline is not selling any shares of Class A common stock in the Offering and will not receive any of the proceeds from the sale.

Goldman Sachs & Co. LLC, Morgan Stanley, BofA Securities and J.P. Morgan are acting as global coordinators and joint bookrunning managers. Barclays, Citigroup, Deutsche Bank Securities, Jefferies, UBS Investment Bank, Evercore ISI, BMO Capital Markets, BNP Paribas, MUFG, RBC Capital Markets, Santander, Societe Generale, TD Cowen, Wells Fargo Securities, Wolfe | Nomura Alliance, Leerink Partners, Macquarie Capital, Mizuho, Piper Sandler, Truist Securities and William Blair are acting as bookrunning managers, and Blackstone Capital Markets, Carlyle, Baird, Rothschild & Co, Stifel, BTIG, ING, IMI – Intesa Sanpaolo, NCMG, Perella Weinberg, Academy Securities, Blaylock Van, LLC, C.L. King & Associates, Drexel Hamilton, Loop Capital Markets, Mischler AmeriVet, R. Seelaus & Co., LLC, Ramirez & Co., Inc., Siebert Williams Shank and Tigress Financial Partners are acting as co-managers for the Offering.

The Offering of these securities is being made only by means of a prospectus. When available, copies of the prospectus relating to this Offering may be obtained from: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 1-866-471-2526, or by email at prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at prospectus@morganstanley.com; BofA Securities, Attention: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001 or by email at dg.prospectus_requests@bofa.com; and J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com.

In addition, as previously announced, Medline and Medline Holdings, LP (“Medline Holdings”) have agreed to repurchase an aggregate of $200 million of Medline’s Class A common stock and limited partnership interests of Medline Holdings (“Common Units”) directly from the Selling Stockholders in a private, non-underwritten transaction at a price per equity interest equal to the price paid by the underwriters in the Offering (the “Repurchase”). To the extent that Common Units are repurchased from a Selling Stockholder, upon closing of the Repurchase, such Selling Stockholder will also transfer an equivalent number of shares of Medline’s Class B common stock to Medline for no additional consideration, and such shares of Class B common stock will be cancelled and retired. The Repurchase is expected to close concurrently with the Offering and is conditioned upon the closing of the Offering. The closing of the Offering is not conditioned upon the closing of the Repurchase. The Repurchase has been approved by the Audit Committee of Medline’s Board of Directors and is pursuant to, and will count toward, Medline’s previously announced share repurchase program.

A registration statement relating to these securities was filed with, and declared effective by, the Securities and Exchange Commission (the “SEC”). This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Medline
Medline is the largest provider of medical-surgical products and supply chain solutions serving all points of care. Through its broad product portfolio, resilient supply chain and leading clinical solutions, Medline helps healthcare providers improve their clinical, financial and operational outcomes. Headquartered in Northfield, Ill., the company employs more than 45,000 people worldwide and operates in more than 100 countries.

Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. Words such as “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “foreseeable,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “seek,” “should,” “will,” or “would,” or similar conditional or future expressions, are intended to identify forward-looking statements. Examples of forward-looking statements include, but are not limited to, statements related to Medline’s industry, business strategy, costs, and cost savings, goals and expectations, market position, future operations, margins, profitability, annual guidance, and other financial and operating information. The forward-looking statements are based on management’s current expectations and are subject to various risks, uncertainties, and changes in circumstances, many of which are beyond Medline’s control, that could cause actual results to differ materially.

Although we believe that the assumptions underlying the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Accordingly, there are or will be important factors that may cause actual results to differ from expected results. These factors include but are not limited to those described under “Risk Factors” in Medline’s registration statement on Form S-1, as amended, relating to the Offering and “Item 1A. Risk Factors” in Medline’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the SEC, as such factors may be updated from time to time in Medline’s periodic filings with the SEC. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Medline’s filings with the SEC. Except as otherwise required by law, we disclaim any intent or obligation to update any “forward-looking statement” made in this press release to reflect changed assumptions, the occurrence of unanticipated events, or changes to future operating results over time.

Contacts:
Investor relations:
Karen King
Global Head, Investor Relations

Patrick Flaherty
Director, Investor Relations

+1.847.247.7222
IR@medline.com

Media relations:
Ben Fox
Vice President, Corporate Communications
+1.224.327.9999
media@medline.com

Source: Medline Inc.


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Medline (MDLN) shares are in the secondary offering, and what is the price?

Existing stockholders are offering 60,000,000 Class A common shares at $35.50 per share to the public. The sellers gave underwriters a 30-day option to buy up to 9,000,000 more shares. Medline will receive no proceeds.

How does Medline’s $200 million buyback relate to the secondary offering?

Medline and Medline Holdings agreed to repurchase $200 million of Class A shares and limited partnership interests directly from the selling stockholders at the price paid by the underwriters. The repurchase depends on the offering closing and will count toward Medline’s existing buyback program. Medline’s board audit committee approved the repurchase.

What happens to Medline’s Class B shares in the buyback tied to the secondary offering?

For each limited partnership interest repurchased from a selling stockholder, that seller will transfer one Class B share to Medline at the repurchase closing for no additional payment. Medline will cancel and retire those shares.

Who is selling shares in Medline’s secondary offering?

The sellers include stockholders affiliated with Blackstone, Carlyle and Hellman & Friedman, along with GIC and its managed affiliate and a wholly owned subsidiary of the Abu Dhabi Investment Authority.

Keep reading